Brief: Santhera Pharmaceuticals Says Reveragen's Vision-DMD Study With Vamorolone In Duchenne Muscular Dystrophy Fully Enrolled

Santhera Pharmaceuticals Holding AG

11/09/2020 06:14

Sept 11 (Reuters) - SANTHERA PHARMACEUTICALS HOLDING AG
 SANN.S :
    * SANTHERA ANNOUNCES FULL ENROLLMENT OF REVERAGEN'S PIVOTAL
VISION-DMD STUDY WITH VAMOROLONE IN DUCHENNE MUSCULAR DYSTROPHY
    * PARTNER REVERAGEN BIOPHARMA INC. HAS COMPLETED ENROLLMENT
INTO
PIVOTAL VISION-DMD STUDY WITH VAMOROLONE IN PATIENTS WITH
DUCHENNE MUSCULAR DYSTROPHY (DMD)
    * SUBJECT TO A POSITIVE STUDY OUTCOME, THIS COULD ALLOW FOR
A
REGULATORY SUBMISSION TO US FDA IN Q4 OF 2021

Source text for Eikon:  ID:nGNEq0n6Q 
Further company coverage:  SANN.S 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))